Group 1 - The core viewpoint of the articles highlights the rapid advancements and regulatory support for brain-computer interface (BCI) technology in China, indicating a significant shift towards clinical applications [1][4][6] - The National Medical Insurance Administration has established pricing guidelines for BCI services, which is seen as a crucial step for the technology's clinical implementation [4][5][6] - Various institutions and companies are actively conducting clinical trials and developing BCI systems, with notable achievements such as the successful implantation of the "North Brain No. 1" system [1][10] Group 2 - BCI technology is categorized into non-invasive, semi-invasive, and invasive methods, each with distinct mechanisms for capturing brain signals [2][3] - The invasive BCI methods have shown to achieve higher precision in signal capture but come with increased risks, while non-invasive methods are more suitable for broader applications [3][8] - The cost of invasive BCI procedures is significantly high, estimated between 300,000 to 500,000 yuan per case, which includes various associated expenses [7] Group 3 - The establishment of pricing standards is expected to facilitate the integration of new technologies into clinical settings, providing a framework for hospitals to conduct large-scale trials [5][6] - The current clinical trials in China are primarily focused on safety and efficacy, with a need for further research on long-term implantation challenges [8][9] - The industry is experiencing a surge in clinical trials and patent applications, positioning China among the leaders in BCI research and development [8][9] Group 4 - The timeline for BCI technology to reach widespread clinical use is projected to be around 2026, with ongoing efforts to establish regulatory standards for clinical trials [10][11][12] - Collaboration among research teams, enterprises, clinical experts, and government bodies is essential for developing approval standards for BCI technologies [12] - The industry is encouraged to pursue innovative research while ensuring that only qualified institutions conduct clinical trials to maintain safety and efficacy [12]